BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 8137212)

  • 1. Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission.
    Dufour P; Bergerat JP; Barats JC; Giron C; Duclos B; Dellenbach P; Ritter J; Renaud R; Audhuy B; Oberling F
    Cancer; 1994 Apr; 73(7):1865-9. PubMed ID: 8137212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consolidation intraperitoneal chemotherapy in epithelial ovarian cancer patients following negative second-look laparotomy.
    Tarraza HM; Boyce CR; Smith WG; Jones MA
    Gynecol Oncol; 1993 Sep; 50(3):287-90. PubMed ID: 8406188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraperitoneal mitoxantrone as consolidation treatment for stage III ovarian carcinoma: a pilot study.
    Dufour P; Maloisel F; Bergerat JP; Barats JC; Dellenbach P; Renaud R; Ritter P; Herbrecht R; Wendling C; Audhuy B
    Bull Cancer; 1991; 78(3):273-80. PubMed ID: 2054526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of ifosfamide and cisplatinum in advanced ovarian cancer.
    Aziz Z; Zahid M; Ud Din Ahmed Z; Arshad T
    Aust N Z J Med; 1998 Jun; 28(3):403-9. PubMed ID: 9673759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term survival with consolidation intraperitoneal chemotherapy for patients with advanced ovarian cancer with pathological complete remission.
    Tournigand C; Louvet C; Molitor JL; Fritel X; Dehni N; Sezeur A; Pigné A; Cady J; Milliez J; de Gramont A
    Gynecol Oncol; 2003 Nov; 91(2):341-5. PubMed ID: 14599864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer.
    Kirmani S; Braly PS; McClay EF; Saltzstein SL; Plaxe SC; Kim S; Cates C; Howell SB
    Gynecol Oncol; 1994 Sep; 54(3):338-44. PubMed ID: 8088611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraperitoneal mitoxantrone or floxuridine: effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy--a randomized phase II study by theSouthwest Oncology Group.
    Muggia FM; Liu PY; Alberts DS; Wallace DL; O'Toole RV; Terada KY; Franklin EW; Herrer GW; Goldberg DA; Hannigan EV
    Gynecol Oncol; 1996 Jun; 61(3):395-402. PubMed ID: 8641622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer.
    Husain A; Sabbatini P; Spriggs D; Fennelly D; Aghajanian C; Barakat R; Curtin J; Venkatraman E; Hoskins W; Markman M
    Gynecol Oncol; 1999 Apr; 73(1):96-101. PubMed ID: 10094887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma.
    Tournigand C; Louvet C; Molitor JL; Dehni N; Lejeune V; Sezeur A; Pigne A; Marpeau L; Cady J; de Gramont A
    Gynecol Oncol; 2001 Nov; 83(2):198-204. PubMed ID: 11606072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-intensive induction therapy with cyclophosphamide, cisplatin, and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer.
    Rothenberg ML; Ozols RF; Glatstein E; Steinberg SM; Reed E; Young RC
    J Clin Oncol; 1992 May; 10(5):727-34. PubMed ID: 1569445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study evaluating consolidation whole abdominal intensity-modulated radiotherapy (IMRT) in patients with advanced ovarian cancer stage FIGO III--the OVAR-IMRT-02 Study.
    Rochet N; Kieser M; Sterzing F; Krause S; Lindel K; Harms W; Eichbaum MH; Schneeweiss A; Sohn C; Debus J
    BMC Cancer; 2011 Jan; 11():41. PubMed ID: 21276234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.
    Louie KG; Ozols RF; Myers CE; Ostchega Y; Jenkins J; Howser D; Young RC
    J Clin Oncol; 1986 Nov; 4(11):1579-85. PubMed ID: 3095501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consolidation with intraperitoneal cisplatin in first-line therapy of advanced ovarian cancer.
    Beller U; Speyer J; Colombo N; Sorich J; Wernz J; Hochster H; Zeleniuch-Jacquotte A; Porges R; Beckman EM
    J Clin Oncol; 1991 May; 9(5):809-17. PubMed ID: 2016624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraperitoneal (ip) cisplatin-mitoxantrone-interferon-alpha 2b in ovarian cancer patients with minimal residual disease.
    Frasci G; Tortoriello A; Facchini G; Conforti S; Cardone A; Persico G; Mastrantonio P; Iaffaioli RV
    Gynecol Oncol; 1993 Jul; 50(1):60-7. PubMed ID: 8349166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
    Armstrong DK; Bundy B; Wenzel L; Huang HQ; Baergen R; Lele S; Copeland LJ; Walker JL; Burger RA;
    N Engl J Med; 2006 Jan; 354(1):34-43. PubMed ID: 16394300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group.
    Varia MA; Stehman FB; Bundy BN; Benda JA; Clarke-Pearson DL; Alvarez RD; Long HJ;
    J Clin Oncol; 2003 Aug; 21(15):2849-55. PubMed ID: 12885800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraperitoneal cisplatin--mitoxantrone in ovarian cancer patients with minimal residual disease.
    Topuz E; Aydiner A; Saip P; Bengisu E; Berkman S; Disci R
    Eur J Gynaecol Oncol; 1997; 18(1):71-5. PubMed ID: 9061330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
    Morgan RJ; Braly P; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Najera L; Johnson D; Doroshow JH
    Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II study of intraperitoneal mitoxantrone in refractory ovarian cancer.
    Oza AM; ten Bokkel Huinink W; Dubbelman R; Soepenberg O; Mandjes I; Aartsen E; McVie JG
    Ann Oncol; 1994 Apr; 5(4):343-7. PubMed ID: 8075031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraperitoneal chemotherapy with mitoxanthrone in ovarian cancer.
    Le Donne M; Messina G; Buda C; Corrado F; Pettineo G; Salimbeni V; Irato S
    Tumori; 1997; 83(5):837-40. PubMed ID: 9428919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.